Highlight
This large-scale, international study involving over 3300 patients with hypertrophic cardiomyopathy (HCM) demonstrates that implantable cardioverter-defibrillators (ICDs) effectively prevent sudden cardiac death by terminating life-threatening ventricular arrhythmias. Key findings include a 16% event rate of appropriate ICD therapies, low device failure rates, and high survival free from HCM-related mortality over two decades.
